Article Text

PDF
The centromeric 11p15 imprinting centre is also involved in Silver–Russell syndrome
  1. Nadine Schönherr1,
  2. Esther Meyer1,
  3. Andreas Roos1,
  4. Angela Schmidt2,
  5. Hartmut A Wollmann3,
  6. Thomas Eggermann1
  1. 1Institute of Human Genetics, RWTH Aachen, Aachen, Germany
  2. 2Praxis für Humangenetik, Hannover, Germany
  3. 3Children’s Hospital, University of Tübingen, Tübingen,Germany
  1. Correspondence to:
 Dr T Eggermann
 Institute of Human Genetics, Pauwelsstr 30, D-52074 Aachen, Germany; teggermann{at}ukaachen.de

Abstract

Silver–Russell syndrome (SRS) is a heterogeneous disorder characterised by severe intrauterine and postnatal growth retardation, limb and body asymmetry, a typical facial appearance and less common dysmorphisms. Recently, epimutations and maternal duplications affecting the short arm of chromosome 11 have been shown to have a crucial role in the aetiology of the disease. Disturbances in the same genomic region cause the overgrowth disorder Beckwith–Wiedemann syndrome (BWS). In BWS, mutations in the telomeric as well as in the centromeric imprinting centres (ICR1 and ICR2) in 11p15 can be observed. In SRS, methylation defects in the imprinted region in 11p15 were considered to be restricted to the telomeric ICR1. They can be detected in about 30% of patients. This article reports on the first patient with SRS with a cryptic duplication restricted to the centromeric ICR2 domain in 11p15. The maternally inherited duplication in this patient included a region of 0.76–1 Mbp and affected the genes regulated by the ICR2, among them CDKN1C and LIT1. This study provides evidence for a role for this imprinting centre in the aetiology of SRS and shows that SRS presents a picture genetically opposite to that of BWS.

  • BWS, Beckwith–Wiedemann syndrome
  • ICR, imprinting centre region
  • OFC, occipitofrontal circumference
  • SRS, Silver–Russell syndrome
  • STR, short tandem repeat

Statistics from Altmetric.com

Footnotes

  • Funding: This work was supported by the Doktor-Robert-Pfleger-Stiftung, Novonordisk Pharma GmbH, and a fellowship of the RWTH, Aachen, Germany (to NS).

  • Competing interests: None declared.

    Further information: Parental/guardian informed consent was obtained for publication of figure 1.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.